http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 27 Aug 2025 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Actinogen+trial+using+intended+commercial+Xanamem+tablet+formulation+confirms+target+exposures+in+fed+and+fasted+states/25257300.html <div class="xn-content"> <p><i>Phase 2b/3 Alzheimer's trial enrolment passes 50% - </i><i>twenty US trial sites continuing to recruit participants </i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ --<b> Actinogen Medical Limited (ASX: ACW)</b> announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and without food, demonstrated the expected blood levels or "exposure", comparable with prior studies of a capsule formulation. This indicates that 10 mg once daily remains the target therapeutic dose for the clinical program.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Actinogen+trial+using+intended+commercial+Xanamem+tablet+formulation+confirms+target+exposures+in+fed+and+fasted+states/25257300.html Wed, 27 Aug 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/Press+Releases/Actinogen+trial+using+intended+commercial+Xanamem+tablet+formulation+confirms+target+exposures+in+fed+and+fasted+states/25257300.html <div class="xn-content"> <p><i>Phase 2b/3 Alzheimer's trial enrolment passes 50% - </i><i>twenty US trial sites continuing to recruit participants </i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ --<b> Actinogen Medical Limited (ASX: ACW)</b> announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and without food, demonstrated the expected blood levels or "exposure", comparable with prior studies of a capsule formulation. This indicates that 10 mg once daily remains the target therapeutic dose for the clinical program.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Actinogen+trial+using+intended+commercial+Xanamem+tablet+formulation+confirms+target+exposures+in+fed+and+fasted+states/25257300.html Wed, 27 Aug 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/PRNewswire/Actinogen+trial+using+intended+commercial+Xanamem+tablet+formulation+confirms+target+exposures+in+fed+and+fasted+states/25257300.html <div class="xn-content"> <p><i>Phase 2b/3 Alzheimer's trial enrolment passes 50% - </i><i>twenty US trial sites continuing to recruit participants </i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ --<b> Actinogen Medical Limited (ASX: ACW)</b> announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and without food, demonstrated the expected blood levels or "exposure", comparable with prior studies of a capsule formulation. This indicates that 10 mg once daily remains the target therapeutic dose for the clinical program.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Actinogen+trial+using+intended+commercial+Xanamem+tablet+formulation+confirms+target+exposures+in+fed+and+fasted+states/25257300.html Wed, 27 Aug 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/PRNewswire/Actinogen+trial+using+intended+commercial+Xanamem+tablet+formulation+confirms+target+exposures+in+fed+and+fasted+states/25257300.html <div class="xn-content"> <p><i>Phase 2b/3 Alzheimer's trial enrolment passes 50% - </i><i>twenty US trial sites continuing to recruit participants </i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Aug. 27, 2025</chron></span> /PRNewswire/ --<b> Actinogen Medical Limited (ASX: ACW)</b> announces that a recent trial designed to confirm therapeutic blood levels of the intended commercial tablet formulation of Xanamem®, given both with and without food, demonstrated the expected blood levels or "exposure", comparable with prior studies of a capsule formulation. This indicates that 10 mg once daily remains the target therapeutic dose for the clinical program.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Actinogen+trial+using+intended+commercial+Xanamem+tablet+formulation+confirms+target+exposures+in+fed+and+fasted+states/25257300.html Wed, 27 Aug 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/Press+Releases/A+novel+oral+treatment+for+Alzheimer%27s%3A+Actinogen%27s+pivotal+trial+currently+recruiting+participants+in+the+US/25078496.html <div class="xn-content"> <p><i>All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem</i><i>®</i><i> vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months</i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>July 22, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW)</b> is encouraging individuals and their loved ones affected by Alzheimer's disease to take part in a groundbreaking clinical trial that could transform the way we treat this devastating condition.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/A+novel+oral+treatment+for+Alzheimer%27s%3A+Actinogen%27s+pivotal+trial+currently+recruiting+participants+in+the+US/25078496.html Tue, 22 Jul 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/Press+Releases/A+novel+oral+treatment+for+Alzheimer%27s%3A+Actinogen%27s+pivotal+trial+currently+recruiting+participants+in+the+US/25078496.html <div class="xn-content"> <p><i>All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem</i><i>®</i><i> vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months</i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>July 22, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW)</b> is encouraging individuals and their loved ones affected by Alzheimer's disease to take part in a groundbreaking clinical trial that could transform the way we treat this devastating condition.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/A+novel+oral+treatment+for+Alzheimer%27s%3A+Actinogen%27s+pivotal+trial+currently+recruiting+participants+in+the+US/25078496.html Tue, 22 Jul 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/PRNewswire/A+novel+oral+treatment+for+Alzheimer%27s%3A+Actinogen%27s+pivotal+trial+currently+recruiting+participants+in+the+US/25078496.html <div class="xn-content"> <p><i>All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem</i><i>®</i><i> vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months</i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>July 22, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW)</b> is encouraging individuals and their loved ones affected by Alzheimer's disease to take part in a groundbreaking clinical trial that could transform the way we treat this devastating condition.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/A+novel+oral+treatment+for+Alzheimer%27s%3A+Actinogen%27s+pivotal+trial+currently+recruiting+participants+in+the+US/25078496.html Tue, 22 Jul 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/PRNewswire/A+novel+oral+treatment+for+Alzheimer%27s%3A+Actinogen%27s+pivotal+trial+currently+recruiting+participants+in+the+US/25078496.html <div class="xn-content"> <p><i>All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem</i><i>®</i><i> vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months</i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>July 22, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW)</b> is encouraging individuals and their loved ones affected by Alzheimer's disease to take part in a groundbreaking clinical trial that could transform the way we treat this devastating condition.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/A+novel+oral+treatment+for+Alzheimer%27s%3A+Actinogen%27s+pivotal+trial+currently+recruiting+participants+in+the+US/25078496.html Tue, 22 Jul 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/Press+Releases/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html <div class="xn-content"> <p><b><i>Interim analysis planned for <chron>January 2026</chron> with final trial results in late 2026</i></b></p> <p><b>Highlights:</b></p> <ul type="disc"><li>With the 100^th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed for <chron>January 2026</chron> and the timeline for final results reconfirmed for late 2026</li><li>An independent Data Monitoring Committee will review all available patient data in <chron>January 2026</chron> after which the results of the review will be announced</li><li>A Type C meeting will be held with the FDA in the second half of 2025 regarding the company's AD program and pathways to regulatory approval.</li></ul><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 30, http://www.streetinsider.com/Press+Releases/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html Mon, 30 Jun 2025 08:30:00 -0400 A.06822034 ACW O.06882960 O.20026344 http://www.streetinsider.com/Press+Releases/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html <div class="xn-content"> <p><b><i>Interim analysis planned for <chron>January 2026</chron> with final trial results in late 2026</i></b></p> <p><b>Highlights:</b></p> <ul type="disc"><li>With the 100^th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed for <chron>January 2026</chron> and the timeline for final results reconfirmed for late 2026</li><li>An independent Data Monitoring Committee will review all available patient data in <chron>January 2026</chron> after which the results of the review will be announced</li><li>A Type C meeting will be held with the FDA in the second half of 2025 regarding the company's AD program and pathways to regulatory approval.</li></ul><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 30, http://www.streetinsider.com/Press+Releases/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html Mon, 30 Jun 2025 08:30:00 -0400 A.06822034 ACW O.06882960 O.20026344 http://www.streetinsider.com/Press+Releases/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html <div class="xn-content"> <p><b><i>Interim analysis planned for <chron>January 2026</chron> with final trial results in late 2026</i></b></p> <p><b>Highlights:</b></p> <ul type="disc"><li>With the 100^th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed for <chron>January 2026</chron> and the timeline for final results reconfirmed for late 2026</li><li>An independent Data Monitoring Committee will review all available patient data in <chron>January 2026</chron> after which the results of the review will be announced</li><li>A Type C meeting will be held with the FDA in the second half of 2025 regarding the company's AD program and pathways to regulatory approval.</li></ul><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 30, http://www.streetinsider.com/Press+Releases/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html Mon, 30 Jun 2025 08:30:00 -0400 A.06822034 ACW O.06882960 O.20026344 http://www.streetinsider.com/Press+Releases/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html <div class="xn-content"> <p><b><i>Interim analysis planned for <chron>January 2026</chron> with final trial results in late 2026</i></b></p> <p><b>Highlights:</b></p> <ul type="disc"><li>With the 100^th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed for <chron>January 2026</chron> and the timeline for final results reconfirmed for late 2026</li><li>An independent Data Monitoring Committee will review all available patient data in <chron>January 2026</chron> after which the results of the review will be announced</li><li>A Type C meeting will be held with the FDA in the second half of 2025 regarding the company's AD program and pathways to regulatory approval.</li></ul><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 30, http://www.streetinsider.com/Press+Releases/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html Mon, 30 Jun 2025 08:30:00 -0400 A.06822034 ACW O.06882960 O.20026344 http://www.streetinsider.com/PRNewswire/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html <div class="xn-content"> <p><b><i>Interim analysis planned for <chron>January 2026</chron> with final trial results in late 2026</i></b></p> <p><b>Highlights:</b></p> <ul type="disc"><li>With the 100^th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed for <chron>January 2026</chron> and the timeline for final results reconfirmed for late 2026</li><li>An independent Data Monitoring Committee will review all available patient data in <chron>January 2026</chron> after which the results of the review will be announced</li><li>A Type C meeting will be held with the FDA in the second half of 2025 regarding the company's AD program and pathways to regulatory approval.</li></ul><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 30, http://www.streetinsider.com/PRNewswire/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html Mon, 30 Jun 2025 08:30:00 -0400 A.06822034 ACW O.06882960 O.20026344 http://www.streetinsider.com/PRNewswire/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html <div class="xn-content"> <p><b><i>Interim analysis planned for <chron>January 2026</chron> with final trial results in late 2026</i></b></p> <p><b>Highlights:</b></p> <ul type="disc"><li>With the 100^th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed for <chron>January 2026</chron> and the timeline for final results reconfirmed for late 2026</li><li>An independent Data Monitoring Committee will review all available patient data in <chron>January 2026</chron> after which the results of the review will be announced</li><li>A Type C meeting will be held with the FDA in the second half of 2025 regarding the company's AD program and pathways to regulatory approval.</li></ul><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 30, http://www.streetinsider.com/PRNewswire/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html Mon, 30 Jun 2025 08:30:00 -0400 A.06822034 ACW O.06882960 O.20026344 http://www.streetinsider.com/PRNewswire/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html <div class="xn-content"> <p><b><i>Interim analysis planned for <chron>January 2026</chron> with final trial results in late 2026</i></b></p> <p><b>Highlights:</b></p> <ul type="disc"><li>With the 100^th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed for <chron>January 2026</chron> and the timeline for final results reconfirmed for late 2026</li><li>An independent Data Monitoring Committee will review all available patient data in <chron>January 2026</chron> after which the results of the review will be announced</li><li>A Type C meeting will be held with the FDA in the second half of 2025 regarding the company's AD program and pathways to regulatory approval.</li></ul><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 30, http://www.streetinsider.com/PRNewswire/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html Mon, 30 Jun 2025 08:30:00 -0400 A.06822034 ACW O.06882960 O.20026344 http://www.streetinsider.com/PRNewswire/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html <div class="xn-content"> <p><b><i>Interim analysis planned for <chron>January 2026</chron> with final trial results in late 2026</i></b></p> <p><b>Highlights:</b></p> <ul type="disc"><li>With the 100^th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed for <chron>January 2026</chron> and the timeline for final results reconfirmed for late 2026</li><li>An independent Data Monitoring Committee will review all available patient data in <chron>January 2026</chron> after which the results of the review will be announced</li><li>A Type C meeting will be held with the FDA in the second half of 2025 regarding the company's AD program and pathways to regulatory approval.</li></ul><p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 30, http://www.streetinsider.com/PRNewswire/Actinogen+confirms+100th+participant+in+XanaMIA+phase+2b3+Alzheimer%27s+disease+trial+and+interim+analysis+timeline/24994788.html Mon, 30 Jun 2025 08:30:00 -0400 A.06822034 ACW O.06882960 O.20026344 http://www.streetinsider.com/Press+Releases/Actinogen+announces+peer-reviewed+clinical+pharmacology+manuscript+for+Xanamem+%28emestedastat%29+published+in+Clinical+Pharmacology+in+Drug+Development+journal/24332622.html <div class="xn-content"> <p><i>Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder</i> </p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW) </b>announces that the publication of its most recent peer-reviewed journal article entitled <i>Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease</i> in Clinical Pharmacology in Drug Development, the journal associated with the <span>American College of Clinical Pharmacology</span>.</p> <div class="PRN_ImbeddedAssetReference" http://www.streetinsider.com/Press+Releases/Actinogen+announces+peer-reviewed+clinical+pharmacology+manuscript+for+Xanamem+%28emestedastat%29+published+in+Clinical+Pharmacology+in+Drug+Development+journal/24332622.html Wed, 12 Feb 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/Press+Releases/Actinogen+announces+peer-reviewed+clinical+pharmacology+manuscript+for+Xanamem+%28emestedastat%29+published+in+Clinical+Pharmacology+in+Drug+Development+journal/24332622.html <div class="xn-content"> <p><i>Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder</i> </p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW) </b>announces that the publication of its most recent peer-reviewed journal article entitled <i>Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease</i> in Clinical Pharmacology in Drug Development, the journal associated with the <span>American College of Clinical Pharmacology</span>.</p> <div class="PRN_ImbeddedAssetReference" http://www.streetinsider.com/Press+Releases/Actinogen+announces+peer-reviewed+clinical+pharmacology+manuscript+for+Xanamem+%28emestedastat%29+published+in+Clinical+Pharmacology+in+Drug+Development+journal/24332622.html Wed, 12 Feb 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/PRNewswire/Actinogen+announces+peer-reviewed+clinical+pharmacology+manuscript+for+Xanamem+%28emestedastat%29+published+in+Clinical+Pharmacology+in+Drug+Development+journal/24332622.html <div class="xn-content"> <p><i>Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder</i> </p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW) </b>announces that the publication of its most recent peer-reviewed journal article entitled <i>Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease</i> in Clinical Pharmacology in Drug Development, the journal associated with the <span>American College of Clinical Pharmacology</span>.</p> <div class="PRN_ImbeddedAssetReference" http://www.streetinsider.com/PRNewswire/Actinogen+announces+peer-reviewed+clinical+pharmacology+manuscript+for+Xanamem+%28emestedastat%29+published+in+Clinical+Pharmacology+in+Drug+Development+journal/24332622.html Wed, 12 Feb 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/PRNewswire/Actinogen+announces+peer-reviewed+clinical+pharmacology+manuscript+for+Xanamem+%28emestedastat%29+published+in+Clinical+Pharmacology+in+Drug+Development+journal/24332622.html <div class="xn-content"> <p><i>Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder</i> </p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Feb. 12, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW) </b>announces that the publication of its most recent peer-reviewed journal article entitled <i>Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease</i> in Clinical Pharmacology in Drug Development, the journal associated with the <span>American College of Clinical Pharmacology</span>.</p> <div class="PRN_ImbeddedAssetReference" http://www.streetinsider.com/PRNewswire/Actinogen+announces+peer-reviewed+clinical+pharmacology+manuscript+for+Xanamem+%28emestedastat%29+published+in+Clinical+Pharmacology+in+Drug+Development+journal/24332622.html Wed, 12 Feb 2025 08:00:00 -0400 ACW O.06882960 http://www.streetinsider.com/Press+Releases/Actinogen+announces+new+and+unique+nonproprietary+name+of+%27emestedastat%27+for+Xanamem/24299473.html <div class="xn-content"> <p class="prntac"><i>Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026</i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Feb. 5, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW) </b>announces that the <span value="ACORN:1756895745" idsrc="xmltag.org" >World Health Organization</span> (<span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem^®/UE2343 once-a-day small molecule in accordance with the <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>'s Procedure for the Selection of Recommended International Nonproprietary Names (INN) for Pharmaceutical Substances.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Actinogen+announces+new+and+unique+nonproprietary+name+of+%27emestedastat%27+for+Xanamem/24299473.html Wed, 05 Feb 2025 09:18:00 -0400 A.17568957 ACW O.04889877 O.06882960 http://www.streetinsider.com/Press+Releases/Actinogen+announces+new+and+unique+nonproprietary+name+of+%27emestedastat%27+for+Xanamem/24299473.html <div class="xn-content"> <p class="prntac"><i>Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026</i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Feb. 5, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW) </b>announces that the <span value="ACORN:1756895745" idsrc="xmltag.org" >World Health Organization</span> (<span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem^®/UE2343 once-a-day small molecule in accordance with the <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>'s Procedure for the Selection of Recommended International Nonproprietary Names (INN) for Pharmaceutical Substances.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Actinogen+announces+new+and+unique+nonproprietary+name+of+%27emestedastat%27+for+Xanamem/24299473.html Wed, 05 Feb 2025 09:18:00 -0400 A.17568957 ACW O.04889877 O.06882960 http://www.streetinsider.com/Press+Releases/Actinogen+announces+new+and+unique+nonproprietary+name+of+%27emestedastat%27+for+Xanamem/24299473.html <div class="xn-content"> <p class="prntac"><i>Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026</i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Feb. 5, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW) </b>announces that the <span value="ACORN:1756895745" idsrc="xmltag.org" >World Health Organization</span> (<span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem^®/UE2343 once-a-day small molecule in accordance with the <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>'s Procedure for the Selection of Recommended International Nonproprietary Names (INN) for Pharmaceutical Substances.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Actinogen+announces+new+and+unique+nonproprietary+name+of+%27emestedastat%27+for+Xanamem/24299473.html Wed, 05 Feb 2025 09:18:00 -0400 A.17568957 ACW O.04889877 O.06882960 http://www.streetinsider.com/Press+Releases/Actinogen+announces+new+and+unique+nonproprietary+name+of+%27emestedastat%27+for+Xanamem/24299473.html <div class="xn-content"> <p class="prntac"><i>Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026</i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Feb. 5, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW) </b>announces that the <span value="ACORN:1756895745" idsrc="xmltag.org" >World Health Organization</span> (<span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem^®/UE2343 once-a-day small molecule in accordance with the <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>'s Procedure for the Selection of Recommended International Nonproprietary Names (INN) for Pharmaceutical Substances.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Actinogen+announces+new+and+unique+nonproprietary+name+of+%27emestedastat%27+for+Xanamem/24299473.html Wed, 05 Feb 2025 09:18:00 -0400 A.17568957 ACW O.04889877 O.06882960 http://www.streetinsider.com/PRNewswire/Actinogen+announces+new+and+unique+nonproprietary+name+of+%27emestedastat%27+for+Xanamem/24299473.html <div class="xn-content"> <p class="prntac"><i>Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026</i></p> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>Feb. 5, 2025</chron></span> /PRNewswire/ -- <b><span value="Australia:ACW" idsrc="xmltag.org" >Actinogen Medical Limited</span> (ASX: ACW) </b>announces that the <span value="ACORN:1756895745" idsrc="xmltag.org" >World Health Organization</span> (<span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem^®/UE2343 once-a-day small molecule in accordance with the <span value="ACORN:1756895745" idsrc="xmltag.org" >WHO</span>'s Procedure for the Selection of Recommended International Nonproprietary Names (INN) for Pharmaceutical Substances.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Actinogen+announces+new+and+unique+nonproprietary+name+of+%27emestedastat%27+for+Xanamem/24299473.html Wed, 05 Feb 2025 09:18:00 -0400 A.17568957 ACW O.04889877 O.06882960